80
Participants
Start Date
September 30, 2005
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Filgrastim
5 mcg/kg, SC daily, start 24 hours after chemotherapy
Pegfilgrastim
6 mg SC one time (24 hours after chemotherapy)
Rituximab
375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
Cyclophosphamide
750 mg/m\^2 IVPB on day 1
Pegylated liposomal doxorubicin hydrochloride
40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
Prednisone
40 mg/m\^2 oral days 1 - 5.
Vincristine Sulfate
2 mg IV, day 1
CCOP - Upstate Carolina, Spartanburg
CCOP - Grand Rapids, Grand Rapids
Cancer Research for the Ozarks, Springfield
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith
CCOP - Kalamazoo, Kalamazoo
Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse
University of Texas M.D. Anderson CCOP Research Base, Houston
Collaborators (1)
National Cancer Institute (NCI)
NIH
Ortho Biotech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER